A Mind Science Company Researching, developing, and manufacturing psychotropic compounds.

Let’s Chat - Contact Us

We Believe

The emerging psychotropics industry will pave the way to a brighter future in mental health and overall wellness.

We believe in Enabling
Market Success.

We believe in Maintaining

We believe in Growth Through

We believe in Our Ethical

What We Do

We are a licensed manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies.


We are dedicated to the production of a variety of high-quality natural, synthetic, and biosynthetic products to meet the needs of the rapidly growing psychotropics-based medicines market.




Single Molecule

White- and Private-Label Products


Driven by a shared passion for mind science, our team is composed of leading experts from pharmaceutical development, biotechnology, agriculture, applied chemistry, and consumer product manufacturing industries.

Board of Directors

Interested in a career with Lucy? See our open positions.


Let’s Chat.

Chris McElvany CEO & President

A pioneer of emerging psychotropic drug markets and co-founder of one of the world’s best selling cannabis products, O.penVAPE, Mr. McElvany leverages more than a decade of experience pushing the boundaries of regulated drug market innovation and successful business operation.

His strategic market positioning and the development and broad licensing of key enabling technologies drove his company, Organa Brands, to an eventual $200 million (USD) acquisition by Slang Worldwide (SLGWF).

Close Icon

Steve Meyer COO

Mr. Meyer's 20+ years of experience in biotechnology R&D and commercial production brings highly valuable strategies and insights to the Lucy team.

Meyer previously served as the North American Operations Lead and Knowledge Transfer Manager for Commercial Operations at Bayer Crop Science (previously Monsanto AG). In 2018, Mr. Meyer began his transition into emerging psychotropics markets, co-founding a large vertical cannabis operation in his home state of Missouri. Early in 2021, having led his cannabis venture to a sustainable and secure future as CEO, Meyer shifted his focus to the broader psychotropics market.

Driven by a lifelong interest in ethnobotany and plant medicine, and guided by his advanced knowledge and education in molecular biology, process improvement, and operational excellence, Mr. Meyer will serve as a dynamic leader and valuable resource for Lucy.

Close Icon

Dr. Jerry Heise CTO

After earning his PhD in Inorganic Chemistry from Purdue University, Dr. Heise set out on a 35-year career on the leading edge of consumer product and biotechnology advancement. Having spent a significant amount of his tenure working for Bayer (Monsanto), Heise served in various key positions, most recently serving as the company's North American Intellectual Property Protection Lead.

Throughout his career, Heise has successfully worked with and led product and process development teams in the U.S. and Canada. Additionally, Dr. Heise has experience educating and collaborating with regulatory bodies and their appointed officers, at one point holding the position of U.S. Biotechnology Regulatory Affairs Manager at Monsanto AG. His continued efforts in this regard will help ensure the safety and sustainability of emerging regulated markets and their products.

Leveraging his wealth of knowledge and experience, Dr. Heise is committed to securing Lucy's endeavors well into the future through the development, application, and protection of highly advanced and effective enabling technologies.

Close Icon

Dr. Assad J. Kazeminy CSO

With a doctorate in pharmaceutical sciences, graduate studies in biochemistry, and a post-doctorate degree in pharmacology, Dr. Kazeminy has over 30 years of research and development experience in the biopharmaceutical industry, earning his place as a highly established authority of emerging biopharmaceutical advancement throughout the U.S. and Canada.

Having founded and served as CEO of Irvine Pharmaceutical Services Inc. and Avrio Biopharmaceutical LLC, Dr. Kazminy has served in a variety of positions over his impressive career, to include membership in the US Pharmacopeia Console of Experts and the UC Irvine Chief Executive Roundtable, to name a few.

Dr. Kazeminy is an expert in the facilitation of qualified trials and brings with him an undeniable track record of implementing best practices to ensure the validity and credibility of research outcomes. Dr. Kazeminy intends to leverage his vast network to enable the Lucy team to best support the psychotropic therapies industry as it continues to mature.

Close Icon

Scott Reeves Board of Director

A leading corporate securities lawyer based in Calgary, Alberta, Canada for more than 25 years, Mr. Reeves leverages a wealth of experience in private and public debt and equity offerings, corporate acquisitions, structuring, and debt financing.

In addition to serving as Partner at TingleMerrett LLP since 2003, Reeves also acts as director of Radiko Holdings, Inc. (2017), Tree of Knowledge International Corp. (2018), Navion Capital Corp. (2018), CBD Global Sciences Inc. (2019), and Starrex International Ltd. (2019).

Close Icon

Brittany Kaiser Board of Director

A globally renowned expert in data protection and privacy, technology policy, and legislative reform, Ms. Kaiser has worked on the leading edge of human-technology interface and education. Utilizing this foundational core of expertise, she has worked with various interdisciplinary teams to design, develop, and refine new technologies and consumer products.

Kaiser is the Co-Founder, President, and Director of the Own Your Data Foundation, and Co-Founder of the Digital Asset Trade Association (DATA) Technology for legal advocacy where she does legislative drafting and lobbying on privacy and blockchain initiatives.

Close Icon

Livio Susin Board of Director

With more than 40 years of experience in early-stage start-up, exploration financing, corporate governance, regulatory affairs, and project management, Mr. Susin represents a litany of strategy knowledge.

Susin is the Founder of Navion Capital Inc., a CPC listed on the TSX where he currently serves on the board of directors. Additionally, he has served on the boards of numerous publicly traded companies including Tock Tech Lithium Inc. and RDS Software, Inc.

Close Icon

Charles Nemeroff Board of Director

As the chair of the Department of Psychiatry and Behavioral Sciences at the University of Texas, Austin, Dell Medical School, Dr. Nemeroff is a highly respected and well-published authority on international mental health research.

Dr. Nemeroff has received multiple awards for research and education in his field and has published more than 1,100 research reports and reviews. Additionally, Nemeroff has served in numerous esteemed board and council positions, including president of the American College of Psychiatrists and the American College of Neuropsychopharmacology.

Close Icon

Paul Abramowitz Board of Director

A leader in corporate finance and strategy development, Mr. Abramowitz has led numerous successful ventures and high-value exits in his 35+ years of business experience. He has successfully helmed more than 20 enterprises driving change through strategic repositioning and organizational transformation.

Mr. Abramowitz founded a baby supply manufacturing company, Pur, leading it to numerous successes until it was acquired by Hasbro, Inc. Additionally, Abramowitz has served in various C-suite capacities, driving continuity and growth for Neah Power Systems, DAK Industries, Inn Keepers of America, and Experience Music Project.

Close Icon